Effect of duloxetine premedication for postherpetic neuralgia within 72 h of herpes zoster reactivation [PROCESS]: a study protocol for a randomized controlled trial

Zheng Chen, Niti Shrestha, Chunmei Zhao, Bifa Fan, Fang Luo, Zheng Chen, Niti Shrestha, Chunmei Zhao, Bifa Fan, Fang Luo

Abstract

Background: Postherpetic neuralgia (PHN) is the most common complication attributed to herpes zoster, which involves the reactivation of residual varicella zoster virus. It has been reported previously that pre-emptive amitriptyline following acute herpes zoster has shown latent positive effects in the prevention of PHN. In this study, by interfering with the same targets, norepinephrine and serotonin, we aim to evaluate whether pre-emptive duloxetine may proactively prevent PHN development.

Methods: This is a nationwide multicentric, randomized, open-label, blinded-endpoint study that will recruit 750 participants from 18 primary centres in China. Patients aged more than 50 years who are diagnosed with uncomplicated HZ, present with vesicles within 72 h of their emergence, and have an average pain score of at least 40/100 mm on a visual analogue scale (VAS, 0 mm = no pain, 100 mm = worst possible pain, at opposite ends of a 100-mm line) will be recruited for this study. Participants will be randomized into a duloxetine arm and a control arm. Participants allocated to the duloxetine arm will be given antivirals, analgesics and duloxetine, while those allocated to the control arm will receive antivirals and analgesics but no duloxetine. The primary outcome of this study is preventive efficacy against PHN, which will be evaluated based on a 100 mm VAS. Any pain scores other than 0 mm on the VAS 12 weeks after HZ onset will be defined as PHN. The secondary outcomes will consist of the average weekly VAS score, the average weekly consumption of each analgesic, weekly feature of the pain, patients' quality of life based on the 12-item Short-Form Health Survey, Patient Global Impression of Change Scale, sleep quality as evaluated by the Pittsburgh Sleep Quality Index and adverse events during the study period.

Discussion: This study will investigate a prophylactic approach for reducing the prevalence of postherpetic neuralgia with duloxetine and will add significant new knowledge on the preventive effects of duloxetine on PHN.

Trial registration: Clinicaltrials.gov NCT04313335 . Registered on 18 March 2020.

Keywords: Duloxetine; Herpes zoster; Postherpetic neuralgia; Prevention.

Figures

Fig. 1
Fig. 1
The timeline and detailed schedule of the PROCESS trial

References

    1. Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Cmaj. 2010;182(16):1731–1736. doi: 10.1503/cmaj.091711.
    1. Yang F, Yu S, Fan B, et al. The epidemiology of herpes zoster and postherpetic neuralgia in China: results from a cross-sectional study. Pain Ther. 2019. 10.1007/s40122-019-0127-z.
    1. Lu L, Suo L, Li J, Pang X. A retrospective survey on herpes zoster disease burden and characteristics in Beijing. China Hum Vaccines Immunother. 2018;14(11):2632–2635. doi: 10.1080/21645515.2018.1489193.
    1. Yu SY, Fan BF, Yang F, et al. Patient and economic burdens of postherpetic neuralgia in China. Clin Outcomes Res. 2019;11:539–550. doi: 10.2147/CEOR.S203920.
    1. Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30–54. doi: 10.1097/j.pain.0000000000000307.
    1. Johnson RW, Rice ASC. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526–1533. doi: 10.1056/NEJMcp1403062.
    1. Schutzer-Weissmann J, Farquhar-Smith P. Post-herpetic neuralgia – a review of current management and future directions. Expert Opin Pharmacother. 2017;18(16):1739–1750. doi: 10.1080/14656566.2017.1392508.
    1. Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations - United States, 2014. MMWR Surveill Summ. 2016;65(1):1–36. doi: 10.15585/mmwr.ss6501a1.
    1. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4). 10.1371/journal.pmed.1001420.
    1. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA - J Am Med Assoc. 2011;305(2):160–166. doi: 10.1001/jama.2010.1983.
    1. Muñoz-Quiles C, López-Lacort M, Orrico-Sánchez A, Díez-Domingo J. Impact of postherpetic neuralgia: a six year population-based analysis on people aged 50 years or older. J Inf Secur. 2018;77(2):131–136. doi: 10.1016/j.jinf.2018.04.004.
    1. Dworkin RH, Perkins FM, Nagasako EM. Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clinical Journal of Pain. 2000;16. 10.1097/00002508-200006001-00016.
    1. Cohen JI. Herpes Zoster. N Engl J Med. 2013;369(3):255–263. doi: 10.1056/NEJMcp1302674.
    1. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2014(2). 10.1002/14651858.CD006866.pub3.
    1. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BKCJ. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. 1994;330:651–5.
    1. Whitley RJ. Acyclovir with and without prednisone for the treatment of herpes zoster. Ann Intern Med. 1996;125(5):376. doi: 10.7326/0003-4819-125-5-199609010-00004.
    1. Ghanavatian S, Wie CS, Low RS, et al. Premedication with gabapentin significantly reduces the risk of postherpetic neuralgia in patients with neuropathy. Mayo Clin Proc. 2019;94(3):484–489. doi: 10.1016/j.mayocp.2018.11.004.
    1. Lapolla W, DiGiorgio C, Haitz K, et al. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol. 2011;147(8):901–907. doi: 10.1001/archdermatol.2011.81.
    1. Bulilete O, Leiva A, Rullán M, et al. Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: a double blind, randomized controlled trial. PLoS One. 2019;14(6):1–17. doi: 10.1371/journal.pone.0217335.
    1. Lee EG, Lee HJ, Hyun DJ, Min K, Kim DH, Yoon MS. Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study. Dermatol Ther. 2016;29(3):184–190. doi: 10.1111/dth.12331.
    1. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manag. 1997;13(6):327–331. doi: 10.1016/S0885-3924(97)00077-8.
    1. Delaney A, Colvin LA, Fallon MT, Dalziel RG, Mitchell R, Fleetwood-Walker SM. Postherpetic neuralgia: from preclinical models to the clinic. Neurotherapeutics. 2009;6(4):630–637. doi: 10.1016/j.nurt.2009.07.005.
    1. Millan MJ. Descending control of pain. Prog Neurobiol. 2002. 10.1016/S0301-0082(02)00009-6.
    1. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi: 10.1016/S1474-4422(14)70251-0.
    1. de Farias ÁD, Eberle L, Amador TA, da Silva Dal Pizzol T. Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews. Adv Rheumatol. 2020;60(1):35. doi: 10.1186/s42358-020-00137-5.
    1. Dunstan DA, Scott N. Clarification of the cut-off score for Zung’s self-rating depression scale. BMC Psychiatry. 2019;19(1):1–7. doi: 10.1186/s12888-019-2161-0.
    1. World Health Organisation. Cancer Pain Relief: a guide to opioid availability. J Infect Dis. 1996. 10.1093/infdis/jir579.
    1. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996. 10.1097/00005650-199603000-00003.
    1. Hurst H, Bolton J. Patients’ Global Impression of Change ( PGIC) scale. J Manip Physiol Ther. 2004.
    1. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989. 10.1016/0165-1781(89)90047-4.
    1. Turcotte JE, Debonnel G, De Montigny C, Hébert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24(5):511–521. doi: 10.1016/S0893-133X(00)00220-7.
    1. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007. 10.1111/j.1526-4637.2006.00258.x.
    1. Wang D, Lai J, Lu S, Huang M, Hu S, Xu Y. Rapid-onset hypo natremia and delirium following duloxetine treatment for postherpetic neuralgia: case report and literature review. Medicine. 2018;97:e13178. doi: 10.1097/MD.0000000000013178.
    1. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials: Blood Press; 1992.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する